World's Best Scientists 2026 revealed!
Francisco Cervantes

Francisco Cervantes

Award Badge
Medicine
Spain
2023

D-Index & Metrics

Medicine

D-Index
99
Citations
59691
World Ranking
8412
National Ranking
120

Francisco Cervantes publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Francisco Cervantes sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 548 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Francisco Cervantes D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Francisco Cervantes sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Francisco Cervantes is affiliated with the University of Barcelona in Spain and has contributed extensively to the field of medicine, particularly focusing on hematology and related subfields. Their research portfolio includes significant work in genetics, molecular biology, rheumatology, and hepatology.

Cervantes' research interests primarily cover clinical and molecular aspects of blood disorders. Key topics explored in their work include:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Kruppel-like factors research
  • Eosinophilic Disorders and Syndromes
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Hemoglobinopathies and Related Disorders

The scientist has published research in a variety of academic journals, demonstrating a broad publication presence. Frequent venues include:

  • Leukemia
  • Journal of Hepatology
  • Clinical Lymphoma Myeloma & Leukemia
  • Annals of Hematology
  • Blood

Among recent published papers, several notable works feature Cervantes as an author. These include:

  • "Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study", 2021, Leukemia
  • "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia", 2020, Leukemia (authored primarily by Andreas Hochhaus with Cervantes contributions in the field)
  • "The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia", 2020, Leukemia (authored primarily by Markus Pfirrmann)
  • "Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis", 2022, Leukemia (authored primarily by Ruben A. Mesa)
  • "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis", 2020, Journal of Hepatology (authored primarily by Marta Magaz)

Cervantes has co-authored publications with several frequent collaborators, including:

  • Alberto Álvarez-Larrán
  • Alessandro M. Vannucchi
  • Ruben A. Mesa
  • Timothy Devos
  • Jean-Jacques Kiladjian

With a cumulative body of 73 publications in medicine, Cervantes' work illustrates a specialized focus on hematology with 22 publications in this subfield and a substantive contribution to genetics with 30 related publications.

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

    Claire Harrison;Jean Jacques Kiladjian;Haifa Kathrin Al-Ali;Heinz Gisslinger

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

    Francisco Cervantes;Brigitte Dupriez;Arturo Pereira;Francesco Passamonti

  • Prognostic discrimination in "good-risk" chronic granulocytic leukemia

    JE Sokal;EB Cox;M Baccarani;S Tura

  • Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

    Thomas Ernst;Andrew J Chase;Andrew J Chase;Joannah Score;Joannah Score;Claire E Hidalgo-Curtis;Claire E Hidalgo-Curtis

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

    Naseema Gangat;Domenica Caramazza;Rakhee Vaidya;Geeta George

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

    Hagop M. Kantarjian;Francis Giles;Norbert Gattermann;Kapil Bhalla

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

    Ayalew Tefferi;Juergen Thiele;Attilio Orazi;Hans Michael Kvasnicka

  • Mutations and prognosis in primary myelofibrosis

    Alessandro Maria Vannucchi;Tl Lasho;Paola Guglielmelli;Flavia Biamonte

  • A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

    Francesco Passamonti;Francisco Cervantes;Alessandro Maria Vannucchi;Enrica Morra

  • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

    Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

    C.N Harrison;A.M. Vannucchi;J.-J. Kiladjian;H.K. Al-Ali

Frequent Co-Authors

Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Francesco Passamonti
Francesco Passamonti University of Milan
Claire N. Harrison
Claire N. Harrison Guy's and St Thomas' NHS Foundation Trust
Emili Montserrat
Emili Montserrat University of Barcelona
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Tiziano Barbui
Tiziano Barbui FROM-Fondazione per la Ricerca Ospedale di Bergamo
Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Giovanni Barosi
Giovanni Barosi University of Pavia
Alessandro Rambaldi
Alessandro Rambaldi University of Milan
Dolors Colomer
Dolors Colomer University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Choosing to study medicine in the USA opens doors to a variety of related healthcare careers and academic pathways. Many students pursue online degrees to build their skills or advance professionally while maintaining flexibility.

For those interested in food science and patient care, an online BS in nutrition can be a strong starting point, offering foundational knowledge in dietetics and wellness.

Aspiring healthcare administrators can benefit from reputable online MHA programs. These master’s degrees, especially those accredited by CAHME, provide essential leadership and management skills for navigating the complex healthcare system.

For registered nurses seeking to advance their qualifications, online RN to BSN programs no clinicals allow for a convenient transition without requiring additional in-person clinical hours, making upskilling more accessible.

Finally, for those aiming for the highest level of nursing practice, the shortest online DNP program options help experienced nurses achieve their doctorate efficiently, opening the door to leadership, research, and education roles.

Best Scientists Citing Francisco Cervantes

Trending Scientists

Recently Published Articles